GCP
CRVO icon

GSA Capital Partners’s CervoMed CRVO Stock Holding History

GSA Capital Partners’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,431
Closed -$209K – 1801
2025
Q4 		$209K Buy
26,431
+15,124
+134% +$122K 0.02% 1387
2025
Q3 		$91K Buy
+11,307
New +$97K 0.01% 1533
2021
Q3 		– Sell
-402
Closed -$22K – 1492
2021
Q2 		$22K Buy
+402
New +$22.2K ﹤0.01% 1281

Other funds holding CRVO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GSA Capital Partners's CRVO Position: Q1 2026 in Review

GSA Capital Partners sold out of CervoMed (CRVO) in Q1 2026, closing a stake of 26,431 shares — an estimated $209K sold.

GSA Capital Partners first reported a position in CRVO in Q2 2021 and held it in 3 quarters. The position peaked at $209K in Q4 2025. 36 funds tracked by Wall St. Rank hold CRVO as of Q1 2026.

  • GSA Capital Partners reported no remaining CervoMed position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 26,431 CervoMed shares in Q1 2026, an estimated $209K.
  • GSA Capital Partners first reported a position in CervoMed in Q2 2021 and held it in 3 quarters.
  • GSA Capital Partners's CervoMed position peaked at $209K in Q4 2025.
  • 36 funds tracked by Wall St. Rank held CervoMed as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.